Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ERBB3 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

ERBB3 overexpression	Colorectal Cancer	ERBB3 overexpression	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
ERBB3 overexpression	Breast Cancer	ERBB3 overexpression	Breast Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	HDAC inhibitor + AKT2 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT2 inhibitor Sensitive : C3	HDAC inhibitor + AKT2 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT2 inhibitor Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	HDAC inhibitor + AKT1 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT1 inhibitor Sensitive : C3	HDAC inhibitor + AKT1 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT1 inhibitor Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	romidepsin Sensitive: C3 – Early Trials romidepsin Sensitive : C3	romidepsin Sensitive: C3 – Early Trials romidepsin Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3
ERBB3 overexpression	Colorectal Cancer	ERBB3 overexpression	Colorectal Cancer	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D